Gut microbiota dysbiosis in inflammatory bowel disease: interaction with intestinal barriers and microbiota-targeted treatment options
Recent studies have deepened our understanding on gut microbiota alterations and the interaction with intestinal barrier impairments, which play a crucial role in the etiology and pathophysiology of Inflammatory bowel disease (IBD). The intestinal microbiota dysbiosis in IBD including the altered mi...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Cellular and Infection Microbiology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcimb.2025.1608025/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849473576101478400 |
|---|---|
| author | Hongjun Xie Hongjun Xie Siyan Yu Siyan Yu Mingyu Tang Mingyu Tang Yating Xun Yating Xun Qin Shen Qin Shen Gaojue Wu Gaojue Wu Gaojue Wu |
| author_facet | Hongjun Xie Hongjun Xie Siyan Yu Siyan Yu Mingyu Tang Mingyu Tang Yating Xun Yating Xun Qin Shen Qin Shen Gaojue Wu Gaojue Wu Gaojue Wu |
| author_sort | Hongjun Xie |
| collection | DOAJ |
| description | Recent studies have deepened our understanding on gut microbiota alterations and the interaction with intestinal barrier impairments, which play a crucial role in the etiology and pathophysiology of Inflammatory bowel disease (IBD). The intestinal microbiota dysbiosis in IBD including the altered microbiota composition, decreased beneficial species and increased harmful species. The disturbed gut microbiota results in the aggravation of intestinal barrier dysfunction through regulation of antimicrobial substances in mucus layer, tight junction protein in mechanical layer and inflammatory response in immune layer. The therapeutic options targeted on the microbiota including antibiotics, probiotics and fecal microbiota transplantation (FMT) exhibit efficacies and limitations in the treatment of IBD. Reasonable single or combined use of these treatments can restore intestinal microecological homeostasis, which further contributes to the treatment of IBD. This review analyzes the underlying mechanisms for the interaction between microbiota alterations and gut barrier dysfunction in IBD; meanwhile, it provides new insights into the microbiota-targeted therapeutic options IBD, including the benefits, risks and limitations of antibiotic and probiotic therapies, unresolved clinical application strategies for FMT, and combination administrations of antibiotics and FMT. |
| format | Article |
| id | doaj-art-a3e01a7011824ee3aaf4ddb9be5724f8 |
| institution | Kabale University |
| issn | 2235-2988 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cellular and Infection Microbiology |
| spelling | doaj-art-a3e01a7011824ee3aaf4ddb9be5724f82025-08-20T03:24:06ZengFrontiers Media S.A.Frontiers in Cellular and Infection Microbiology2235-29882025-06-011510.3389/fcimb.2025.16080251608025Gut microbiota dysbiosis in inflammatory bowel disease: interaction with intestinal barriers and microbiota-targeted treatment optionsHongjun Xie0Hongjun Xie1Siyan Yu2Siyan Yu3Mingyu Tang4Mingyu Tang5Yating Xun6Yating Xun7Qin Shen8Qin Shen9Gaojue Wu10Gaojue Wu11Gaojue Wu12Department of Gastroenterology, Wuxi No. 2 People’s Hospital, Affiliated Wuxi Clinical College of Nantong University, Wuxi, Jiangsu, ChinaSchool of Medicine, Nantong University, Nantong, Jiangsu, ChinaSchool of Medicine, Nantong University, Nantong, Jiangsu, ChinaWuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, ChinaSchool of Medicine, Nantong University, Nantong, Jiangsu, ChinaWuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, ChinaDepartment of Gastroenterology, Wuxi No. 2 People’s Hospital, Affiliated Wuxi Clinical College of Nantong University, Wuxi, Jiangsu, ChinaSchool of Medicine, Nantong University, Nantong, Jiangsu, ChinaSchool of Medicine, Nantong University, Nantong, Jiangsu, ChinaWuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, ChinaDepartment of Gastroenterology, Wuxi No. 2 People’s Hospital, Affiliated Wuxi Clinical College of Nantong University, Wuxi, Jiangsu, ChinaSchool of Medicine, Nantong University, Nantong, Jiangsu, ChinaWuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, ChinaRecent studies have deepened our understanding on gut microbiota alterations and the interaction with intestinal barrier impairments, which play a crucial role in the etiology and pathophysiology of Inflammatory bowel disease (IBD). The intestinal microbiota dysbiosis in IBD including the altered microbiota composition, decreased beneficial species and increased harmful species. The disturbed gut microbiota results in the aggravation of intestinal barrier dysfunction through regulation of antimicrobial substances in mucus layer, tight junction protein in mechanical layer and inflammatory response in immune layer. The therapeutic options targeted on the microbiota including antibiotics, probiotics and fecal microbiota transplantation (FMT) exhibit efficacies and limitations in the treatment of IBD. Reasonable single or combined use of these treatments can restore intestinal microecological homeostasis, which further contributes to the treatment of IBD. This review analyzes the underlying mechanisms for the interaction between microbiota alterations and gut barrier dysfunction in IBD; meanwhile, it provides new insights into the microbiota-targeted therapeutic options IBD, including the benefits, risks and limitations of antibiotic and probiotic therapies, unresolved clinical application strategies for FMT, and combination administrations of antibiotics and FMT.https://www.frontiersin.org/articles/10.3389/fcimb.2025.1608025/fullinflammatory bowel diseasegut microbiotaintestinal barrierfecal microbiota transplantationantibioticsprobiotics |
| spellingShingle | Hongjun Xie Hongjun Xie Siyan Yu Siyan Yu Mingyu Tang Mingyu Tang Yating Xun Yating Xun Qin Shen Qin Shen Gaojue Wu Gaojue Wu Gaojue Wu Gut microbiota dysbiosis in inflammatory bowel disease: interaction with intestinal barriers and microbiota-targeted treatment options Frontiers in Cellular and Infection Microbiology inflammatory bowel disease gut microbiota intestinal barrier fecal microbiota transplantation antibiotics probiotics |
| title | Gut microbiota dysbiosis in inflammatory bowel disease: interaction with intestinal barriers and microbiota-targeted treatment options |
| title_full | Gut microbiota dysbiosis in inflammatory bowel disease: interaction with intestinal barriers and microbiota-targeted treatment options |
| title_fullStr | Gut microbiota dysbiosis in inflammatory bowel disease: interaction with intestinal barriers and microbiota-targeted treatment options |
| title_full_unstemmed | Gut microbiota dysbiosis in inflammatory bowel disease: interaction with intestinal barriers and microbiota-targeted treatment options |
| title_short | Gut microbiota dysbiosis in inflammatory bowel disease: interaction with intestinal barriers and microbiota-targeted treatment options |
| title_sort | gut microbiota dysbiosis in inflammatory bowel disease interaction with intestinal barriers and microbiota targeted treatment options |
| topic | inflammatory bowel disease gut microbiota intestinal barrier fecal microbiota transplantation antibiotics probiotics |
| url | https://www.frontiersin.org/articles/10.3389/fcimb.2025.1608025/full |
| work_keys_str_mv | AT hongjunxie gutmicrobiotadysbiosisininflammatoryboweldiseaseinteractionwithintestinalbarriersandmicrobiotatargetedtreatmentoptions AT hongjunxie gutmicrobiotadysbiosisininflammatoryboweldiseaseinteractionwithintestinalbarriersandmicrobiotatargetedtreatmentoptions AT siyanyu gutmicrobiotadysbiosisininflammatoryboweldiseaseinteractionwithintestinalbarriersandmicrobiotatargetedtreatmentoptions AT siyanyu gutmicrobiotadysbiosisininflammatoryboweldiseaseinteractionwithintestinalbarriersandmicrobiotatargetedtreatmentoptions AT mingyutang gutmicrobiotadysbiosisininflammatoryboweldiseaseinteractionwithintestinalbarriersandmicrobiotatargetedtreatmentoptions AT mingyutang gutmicrobiotadysbiosisininflammatoryboweldiseaseinteractionwithintestinalbarriersandmicrobiotatargetedtreatmentoptions AT yatingxun gutmicrobiotadysbiosisininflammatoryboweldiseaseinteractionwithintestinalbarriersandmicrobiotatargetedtreatmentoptions AT yatingxun gutmicrobiotadysbiosisininflammatoryboweldiseaseinteractionwithintestinalbarriersandmicrobiotatargetedtreatmentoptions AT qinshen gutmicrobiotadysbiosisininflammatoryboweldiseaseinteractionwithintestinalbarriersandmicrobiotatargetedtreatmentoptions AT qinshen gutmicrobiotadysbiosisininflammatoryboweldiseaseinteractionwithintestinalbarriersandmicrobiotatargetedtreatmentoptions AT gaojuewu gutmicrobiotadysbiosisininflammatoryboweldiseaseinteractionwithintestinalbarriersandmicrobiotatargetedtreatmentoptions AT gaojuewu gutmicrobiotadysbiosisininflammatoryboweldiseaseinteractionwithintestinalbarriersandmicrobiotatargetedtreatmentoptions AT gaojuewu gutmicrobiotadysbiosisininflammatoryboweldiseaseinteractionwithintestinalbarriersandmicrobiotatargetedtreatmentoptions |